Get emergency medical help if you have signs of an allergic reaction (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning eyes, skin pain, red or purple skin rash with blistering and peeling)
[15] Concerns regarding the use of efavirenz in patients with a history of mental illness may predispose clinicians to not offer this agent to psychiatrically ill populations in spite of the convenience of once daily dosing, which can result in improved adherence in these at-risk populations
( 3, 4) Taking into consideration the increasing access to ART, the potential for EFV exposure in world population is very large
A novel, enantioselective addition of Li-cyclopropyl acetylide (4a) to p-methoxybenzyl-protected
Some people taking efavirenz, a component of Symfi, may develop liver problems
For individuals with a history of virologic failure and NRTI resistance who have suppressed viral loads on a boosted PI with 2 NRTIs, the new regimen should consist of dolutegravir (or bictegravir) Efavirenz can commonly cause a rash that is usually not serious
Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil
He has taken efavirenz-tenofovir DF-emtricitabine for 7 years with suppressed HIV RNA levels, but he has developed some mild depression
Approval History Drug history at FDA
Related Drugs Efavirenz, lamivudine and tenofovir disoproxil fumarate tablets are three-drug combination of efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor, and lamivudine (3TC) and tenofovir disoproxil fumarate (TDF), both nucleo(t)side reverse transcriptase inhibitors and are indicated as a complete regimen for the treatment of
FDA Approved: Yes (First approved July 12, 2006) Brand name: Atripla Generic name: efavirenz, emtricitabine and tenofovir disoproxil fumarate Dosage form: Tablets Company: Bristol-Myers Squibb Company / Gilead Sciences, Inc
Efavirenz signi cantly decreases voriconazole plasma concentrations, and coadministration may decrease the therapeutic effectiveness of voriconazole